Portfolio concentration
As of March 31, 2026 · N-PORT
Holdings
104
Top-10 weight
43.14%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
37
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
922.5
Holdings
As of March 31, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | UCB SA | — | 130,137 | $39.21M | 5.90% |
| 2 | REGENERON PHARMACEUTICALS INC | — | 47,000 | $36.31M | 5.46% |
| 3 | PFIZER INC | — | 1,145,000 | $32.15M | 4.84% |
| 4 | GILEAD SCIENCES INC | — | 210,000 | $29.27M | 4.40% |
| 5 | ABBVIE INC | — | 125,000 | $27.19M | 4.09% |
| 6 | MERCK & CO | — | 215,000 | $25.86M | 3.89% |
| 7 | ASTRAZENECA PLC | — | 131,243 | $25.66M | 3.86% |
| 8 | CHUGAI PHARMA CO | — | 450,000 | $24.82M | 3.73% |
| 9 | LILLY ELI and CO | — | 26,000 | $23.91M | 3.60% |
| 10 | ROCHE HOLDING AG | — | 55,000 | $21.95M | 3.30% |
| 11 | UNITEDHEALTH GRP | — | 70,000 | $18.94M | 2.85% |
| 12 | ELEVANCE HEALTH INC | — | 63,000 | $18.44M | 2.77% |
| 13 | AMGEN INC | — | 47,000 | $16.54M | 2.49% |
| 14 | VIATRIS INC | — | 1,170,018 | $15.81M | 2.38% |
| 15 | BOSTON SCIENTIFIC CORP | — | 250,000 | $15.69M | 2.36% |
| 16 | HALOZYME THERAPEUTICS INC | — | 220,000 | $14.22M | 2.14% |
| 17 | Sanofi SA | — | 120,000 | $11.59M | 1.74% |
| 18 | VERTEX PHARMACEUTICALS INC | — | 25,000 | $11.16M | 1.68% |
| 19 | ILLUMINA INC | — | 90,000 | $11.09M | 1.67% |
| 20 | VIKING THERAPEUTICS INC | — | 330,100 | $10.74M | 1.62% |
| 21 | ALKERMES PLC | — | 290,000 | $10.25M | 1.54% |
| 22 | ALNYLAM PHARMACEUTICALS INC | — | 30,000 | $9.93M | 1.49% |
| 23 | FEDERAL NATIONAL MORTGAGE ASSOCIATION | FNMA | 1,300,000 | $9.44M | 1.42% |
| 24 | ROIVANT SCIENCES LTD | — | 338,181 | $9.37M | 1.41% |
| 25 | NEUROCRINE BIOSCIENCES INC | — | 70,000 | $9.22M | 1.39% |
| 26 | COGENT BIOSCIENCES INC | — | 230,000 | $8.85M | 1.33% |
| 27 | ARCUS BIOSCIENCES INC | — | 379,100 | $8.19M | 1.23% |
| 28 | INCYTE CORP | — | 80,000 | $7.53M | 1.13% |
| 29 | ZIMMER BIOMET HO | — | 80,000 | $7.23M | 1.09% |
| 30 | TARSUS PHARMACEUTICALS INC | — | 100,000 | $7.02M | 1.05% |
| 31 | FREDDIE MAC | FMCC | 1,050,000 | $6.72M | 1.01% |
| 32 | QUEST DIAGNOSTICS INC | — | 30,000 | $5.88M | 0.88% |
| 33 | BIOMARIN PHARMACEUTICAL INC | — | 100,000 | $5.65M | 0.85% |
| 34 | CVS HEALTH CORP | — | 75,000 | $5.39M | 0.81% |
| 35 | MONEYMKT | FIGXX | 5,357,802 | $5.36M | 0.81% |
| 36 | BlackRock Liquidity FedFund - Institutional Class | TFDXX | 5,357,802 | $5.36M | 0.81% |
| 37 | MSILF-GOVT-INS | MVRXX | 5,357,802 | $5.36M | 0.81% |
| 38 | MONEYMKT | FGTXX | 5,357,802 | $5.36M | 0.81% |
| 39 | ANAPTYSBIO INC | — | 93,732 | $5.20M | 0.78% |
| 40 | BIOGEN INC | — | 28,000 | $5.13M | 0.77% |
| 41 | Abivax SA SPONSORED ADS | ABVX US | 45,000 | $5.01M | 0.75% |
| 42 | STRYKER CORP | — | 15,000 | $4.93M | 0.74% |
| 43 | JOHNSON&JOHNSON | — | 20,000 | $4.89M | 0.74% |
| 44 | VIR BIOTECHNOLOGY INC | — | 500,000 | $4.48M | 0.67% |
| 45 | GRAIL INC | — | 85,000 | $4.39M | 0.66% |
| 46 | RIGEL PHARMACEUTICALS INC | — | 160,000 | $4.33M | 0.65% |
| 47 | UNIQURE N.V. | — | 258,211 | $4.22M | 0.63% |
| 48 | SYNDAX PHARMACEUTICALS INC | — | 180,000 | $4.20M | 0.63% |
| 49 | MADRIGAL PHARMACEUTICALS INC | — | 7,000 | $3.66M | 0.55% |
| 50 | THERAVANCE BIOPHARMA INC | — | 208,783 | $3.39M | 0.51% |
1 / 3
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.